

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

SECRETARY OF THE SENATE

03 SEP -5 PM 5:06

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name Kos Pharmaceuticals, Inc.			
2. Address <input type="checkbox"/> Check if different than previously reported 1001 Brickell Bay Drive, 25th Floor			
3. Principal Place of Business (if different from line 2) City: Miami State/Zip (or Country) FL 33131			
4. Contact Name Constance Bienfait	Telephone 305-577-3464	E-mail (optional)	5. Senate ID #
7. Client Name Self <input checked="" type="checkbox"/> Kos Pharmaceuticals, Inc.			6. House ID #

TYPE OF REPORT 8. Year 2003 Midyear (January 1-June 30) OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report 10. Check if this is a Termination Report ⇒ Termination Date _____ 11. No Lobbying Activity **INCOME OR EXPENSES** - Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organizations
<p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> ⇒ \$ <u> </u> Income (nearest (\$20,000))</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇒ \$ <u> 40,000 </u> Income (nearest (\$20,000))</p> <p>14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options.</p> <p><input type="checkbox"/> Method A. Reporting amounts using LDA definitions only</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code</p>

Signature

Constance C. Bienfait Date 09/14/03

Printed Name and Title Constance Bienfait, Executive Director, Corporate Communications

Registrant Name Kos Pharmaceuticals, Inc. Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code PHA (One per page)

16. Specific lobbying issues

**S. 54 - Greater Access to Affordable Pharmaceuticals Act
 S 1/ HR 1 – Prescription Drug and Medicare Modernization Act
 HR 2427 – Pharmaceutical Market Access Act of 2003
 Various Drug Reimportation and Generic Drug Proposals**

17. House(s) of Congress and Federal agencies contacted Check if None

**United States House of Representatives
 United States Senate**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Mr. Michael Jaharis	Chairman Emeritus
Mr. Adrian Adams	President and CEO
Ms. Constance Bienfait	Executive Director, Corporate Communications

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature Constance C Bienfait Date 9/18/03

Registrant Name Kos Pharmaceuticals, Inc. Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (One per page)

16. Specific lobbying issues

**S. 54 - Greater Access to Affordable Pharmaceuticals Act
 S 1/ HR 1 - Prescription Drug and Medicare Modernization Act
 HR 2427 - Pharmaceutical Market Access Act of 2003
 Various Drug Reimportation and Generic Drug Proposals**


17. House(s) of Congress and Federal agencies contacted Check if None

**United States House of Representatives
 United States Senate**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Mr. Michael Jaharis	Chairman Emeritus
Mr. Adrian Adams	President and CEO
Ms. Constance Bienfait	Executive Director, Corporate Communications

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date 9/18/03

Printed Name and Title Ms. Constance Bienfait, Executive Director Corporate Communications

Registrant Name Kos Pharmaceuticals, Inc. Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (One per page)

16. Specific lobbying issues

**S. 54 - Greater Access to Affordable Pharmaceuticals Act
 S 1/ HR 1 – Prescription Drug and Medicare Modernization Act
 HR 2427 – Pharmaceutical Market Access Act of 2003
 Various Drug Reimportation and Generic Drug Proposals**


17. House(s) of Congress and Federal agencies contacted Check if None

**United States House of Representatives
 United States Senate**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Mr. Michael Jaharis	Chairman Emeritus
Mr. Adrian Adams	President and CEO
Ms. Constance Bienfait	Executive Director, Corporate Communications

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date 9/8/03

Printed Name and Title Ms. Constance Bienfait, Executive Director Corporate Communications

Registrant Name Kos Pharmaceuticals, Inc. Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MED (One per page)

16. Specific lobbying issues

**S. 54 - Greater Access to Affordable Pharmaceuticals Act
S 1/ HR 1 – Prescription Drug and Medicare Modernization Act
HR 2427 – Pharmaceutical Market Access Act of 2003
Various Drug Reimportation and Generic Drug Proposals**

17. House(s) of Congress and Federal agencies contacted Check if None

**United States House of Representatives
United States Senate**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Mr. Michael Jaharis	Chairman Emeritus
Mr. Adrian Adams	President and CEO
Ms. Constance Bienfait	Executive Director, Corporate Communications

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature *Constance C. Bienfait* Date 9/4/03

Printed Name and Title Ms. Constance Bienfait, Executive Director, Corporate Communications

Registrant Name Kos Pharmaceuticals, Inc. Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (One per page)

16. Specific lobbying issues

Patent Extension and Market Exclusivity Regulations


17. House(s) of Congress and Federal agencies contacted Check if None

**United States House of Representatives
United States Senate**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Mr. Michael Jaharis	Chairman Emeritus
Mr. Adrian Adams	President and CEO
Ms. Constance Bienfait	Executive Director, Corporate Communications

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date 9/4/03

Printed Name and Title Ms. Constance Bienfait, Executive Director Corporate Communications

